IL325692A - פורמולציות מיוצבות הכוללות נוגדנים ביספציפיים נגד bcma ונגד cd3 - Google Patents

פורמולציות מיוצבות הכוללות נוגדנים ביספציפיים נגד bcma ונגד cd3

Info

Publication number
IL325692A
IL325692A IL325692A IL32569225A IL325692A IL 325692 A IL325692 A IL 325692A IL 325692 A IL325692 A IL 325692A IL 32569225 A IL32569225 A IL 32569225A IL 325692 A IL325692 A IL 325692A
Authority
IL
Israel
Prior art keywords
bcma
bispecific antibodies
formulations containing
stabilized formulations
containing anti
Prior art date
Application number
IL325692A
Other languages
English (en)
Inventor
Kenneth S Graham
Saurabh Wadhwa
Douglas Kamen
Original Assignee
Regeneron Pharma
Kenneth S Graham
Saurabh Wadhwa
Douglas Kamen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Kenneth S Graham, Saurabh Wadhwa, Douglas Kamen filed Critical Regeneron Pharma
Publication of IL325692A publication Critical patent/IL325692A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
IL325692A 2023-07-07 2025-12-30 פורמולציות מיוצבות הכוללות נוגדנים ביספציפיים נגד bcma ונגד cd3 IL325692A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363525652P 2023-07-07 2023-07-07
US202363613540P 2023-12-21 2023-12-21
PCT/US2024/036933 WO2025014823A1 (en) 2023-07-07 2024-07-05 Stabilized formulations containing anti-bcma x anti-cd3 bispecific antibodies

Publications (1)

Publication Number Publication Date
IL325692A true IL325692A (he) 2026-02-01

Family

ID=91961849

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325692A IL325692A (he) 2023-07-07 2025-12-30 פורמולציות מיוצבות הכוללות נוגדנים ביספציפיים נגד bcma ונגד cd3

Country Status (12)

Country Link
US (1) US20250041411A1 (he)
EP (1) EP4739710A1 (he)
JP (1) JP2026524485A (he)
KR (1) KR20260036335A (he)
CN (1) CN121464156A (he)
AU (1) AU2024297316A1 (he)
CL (1) CL2026000030A1 (he)
CO (1) CO2026000834A2 (he)
IL (1) IL325692A (he)
MX (1) MX2026000123A (he)
TW (1) TW202517293A (he)
WO (1) WO2025014823A1 (he)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
AU2020370372A1 (en) * 2019-10-25 2022-05-12 Amgen Inc. Compositions and methods for minimizing protein loss at low protein concentrations
JP7693672B2 (ja) * 2019-12-06 2025-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
EP4426437A4 (en) * 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
WO2023086817A1 (en) * 2021-11-10 2023-05-19 Janssen Biotech, Inc. Stable formulations comprising a bispecific bcma/cd3 antibody

Also Published As

Publication number Publication date
WO2025014823A1 (en) 2025-01-16
CO2026000834A2 (es) 2026-02-13
EP4739710A1 (en) 2026-05-13
CL2026000030A1 (es) 2026-04-10
JP2026524485A (ja) 2026-07-22
MX2026000123A (es) 2026-03-02
US20250041411A1 (en) 2025-02-06
AU2024297316A1 (en) 2026-01-29
TW202517293A (zh) 2025-05-01
CN121464156A (zh) 2026-02-03
KR20260036335A (ko) 2026-03-16

Similar Documents

Publication Publication Date Title
IL307879A (he) פורמולציות נוגדנים ביספציפיים בריכוז גבוה
IL312700A (he) פורמולציות יציבות המכילות נוגדן ביספציפי bcma/cd3
SG11202109822XA (en) Stabilized formulations containing anti-il-33 antibodies
ZA202310292B (en) Anti-cldn4/anti-cd137 bispecific antibody
IL320432A (he) תרכובות נוגדנים ביספציפיות
IL306042A (he) פורמולציות מיוצבות כוללות נוגדנים ביספציפיים נגד muc16 ו-cd3
CA3261147A1 (en) DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
CA3297636A1 (en) Stabilized formulations containing anti-bcma x anti-cd3 bispecific antibodies
HK40106470A (en) Stabilized formulations containing anti-muc16 x anti-cd3 bispecific antibodies
CA3260186A1 (en) Formulations for Bispecific Antibodies: Anti-PD-L1/Anti-4-1BB
IL299152A (he) פורמולציות מיוצבות הכוללות נוגדנים נגד ctla-4
IL321509A (he) נוגדנים דו-ספציפיים מסוג cd28/ox40
IL318297A (he) פורמולציות נוגדן נגד tl1a
HK40082040A (en) Stabilized formulations containing anti-cd20 x anti-cd3 bispecific antibodies
IL320411A (he) Anti-cd3 נוגדנים
HK40119561A (en) Formulations for anti-pd-l1/anti-4-1bb bispecific antibodies
IL314840A (he) פורמולציות יציבות לנוגדנים
IL319755A (he) פורמולציות לנוגדנים אנטי- c1q
GB202312575D0 (en) Bispecific antibodies
CA3291313A1 (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
HK40126940A (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3261510A1 (en) DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
HK40117060A (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
HK40121846A (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
GB202507161D0 (en) Bispecific antibody